Clinical pharmacokinetics of sirolimus

Clinical Pharmacokinetics

Volumn 40, Issue 8, 2001, Pages 573-585

  Mahalati, Kamran ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16 O NORSIROLIMUS; 27,39 O DINORSIROLIMUS; 39 O NORSIROLIMUS; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A4; DIHYDROXYSIROLIMUS; DILTIAZEM; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; KETOCONAZOLE; LACTONE DERIVATIVE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MICROPARTICLE ENZYME IMMUNOASSAY; NONHUMAN; PRIORITY JOURNAL; RADIORECEPTOR ASSAY; REVIEW; TANDEM MASS SPECTROMETRY;

EID: 0034870203     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140080-00002     Document Type: Review

References (60)

1. Rapamycin (AY-22,989), a new antifungal antibiotic: II. Fermentation, isolation and characterization
2. The rejection of renal homograft inhibition in dogs by 6-mercaptopurine
3. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin
4. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro
5. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats
6. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin
7. Stability of sirolimus (rapamycin) in whole blood
8. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy
9. Established immunosuppressive drugs: Clinical and toxic effects
10. Sirolimus-tacrolimus combination immunosuppression
11. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin
12. Rapamycin: Distribution, pharmacokinetics, and therapeutic range investigations
13. Blood distribution of rapamycin
14. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry
15. Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry
16. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations
17. Comparison of steady-state trough sirolimus samples by HPLC and a radioreceptor assay
18. Analytical performance of microparticle enzyme immunoassay and HPLC-tandem mass spectrometry in the determination of sirolimus in whole blood
19. Determination of rapamycin in whole blood by HPLC
20. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
21. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection
22. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection
23. Comparison of binding characteristics of four rapamycin metabolites to the 14 and 52 kDa immunophilins with their pharmacologic activity measured by the mixed-lymphocyte culture assay
24. Minor immunophilin binding of tacrolimus and sirolimus metabolites
25. Radioreceptor assay for sirolimus in patients with decreased platelet counts
26. The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients
27. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients
28. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin)
29. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients
30. Pharmacokinetics of rapamycin
31. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration
32. Population pharmacokinetics of sirolimus in kidney transplant patients
33. Sirolimus oral solution and tablets demonstrate equivalent safety and efficacy in renal allografts
34. Comparison of the pharmacokinetics of sirolimus (Rapamune) in renal transplant recipients following administration of the liquid or solid table formations
35. Conversion from liquid to solid sirolimus formulations in stable renal allograft transplant recipients
36. A comparative study of the pharmacokinetic profiles of sirolimus oral solution and tablets in renal allograft patients
37. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation co-administration on the pharmacokinetics of each agent
38. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes
39. Uptake of FK 506 by lymphocytes and erythrocytes
40. Effect of sirolimus on the metabolism of ApoB-100 containing lipoproteins in renal transplant patients
41. Distribution of sirolimus in rat tissue
42. Role of intestinal P-glycoprotein (mdr 1) in interpatient variation in the oral bioavailability of cyclosporine
43. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine
44. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
45. In vitro and in situ absorption of SDZRAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin
46. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
47. Rapamycin: Distribution, pharmacokinetics and therapeutic range investigations: An update
48. High performance liquid chromatographic isolation, spectroscopic characterization and immunosuppressive activities of two rapamycin degradation products
49. High performance liquid chromatographic isolation and spectroscopic characterization of three major metabolites from the plasma of rats receiving rapamycin (sirolimus) orally
50. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interactions
51. Sirolimus (Rapamune, rapamycin) is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: A phase III U.S. multicenter trial
52. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants
53. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model
54. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
55. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial
56. Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
57. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
58. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression [brief communication]
59. A calcineurin-free strategy for induction immunosuppression for delayed graft function in cadaveric kidney transplantation